ZNTL / azenosertib-cyclin-e1-proc — azenosertib (ZN-c3) for Cyclin E1-positive platinum-resistant ovarian cancer

Program analysis · bpiq_drug_id 17802 · prepared 2026-08 · USD · framework v5.6.1 · Coverage: CLEARED

Company context, financials, ownership, options and the full pipeline: ../company.md.

How to read this. Written for a reader who has not studied pharmacology or finance. Terms specific to this program are in the Glossary below; general terms are defined once in framework/04-glossary.md. Tags: [VERIFIED — source] / [UNVERIFIED] / [WEB ESTIMATE — source, date].

Glossary

Executive summary

• What it is. Azenosertib is a once-daily tablet that blocks WEE1, a brake on cell division. Blocking that brake kills tumours that make too much of a protein called Cyclin E1, because those tumours are already dividing under strain and need the brake to survive. About half of platinum-resistant ovarian cancers are in this group, and they have no targeted drug today. [VERIFIED — CT.gov NCT05128825; NPJ Precision Oncology 2025, DOI 10.1038/s41698-024-00787-4]
• The event and when. The pivotal trial, DENALI Part 2, reports its integrated topline in the first half of 2027. That is new: on 2026-08-06 the company moved the date from “year-end 2026” — guidance it had repeated unchanged seven times over fifteen months — “to allow for data maturation post full enrollment”. The shares fell about 16% on the change. Before the topline, the company presents survival data from the earlier part of the same trial at a cancer conference on 23 October 2026. [VERIFIED — Q2 2026 results release 2026-08-06; BPIQ drug row 17802; company release 2026-07-17]
• The main reason it could work. The earlier part of the same trial used the same 400 mg dose and produced a 31.3% response rate in Cyclin E1-positive patients. The company compared 400 mg against 300 mg in a prespecified interim look, picked 400 mg, started a Phase 3, and paid a $7.0 million milestone to do so. In 2026 the FDA reviewed the strategy in a Type D meeting, had no objection to the dose, and acknowledged the study population has the potential to support an accelerated approval. The FDA has already approved a different drug in this exact disease on this exact kind of trial. [VERIFIED — SGO 2025 via OncLive; company releases 2026-04-09 and 2026-08-06; Zentalis Form 10-K]
• The main risk. The 31.3% figure came from a patient group picked out after the results were in. Such subgroups usually weaken when tested properly, and the integrated readout now folds in a cohort of even more heavily pre-treated patients. Separately, the drug’s main side effect is low blood counts, which caused two deaths from infection and a temporary FDA halt in 2024. And the balance-sheet cushion has thinned: the readout moved six months further out while a quarter of cash burned. [VERIFIED — OncLive; company releases; ../company.md C.3]
• What it means for the stock. The shares de-rated 16% on the slip and now sit at $4.16, near the middle of their 52-week range. The business is valued at roughly $124 million of enterprise value against a base case of several hundred million dollars a year in sales if the drug is approved. We lean positive on the trial result at 55% and call the shares up with low confidence over the readout window.

0. Program-tier coverage — CLEARED

The regulatory tier is not called: this program’s catalyst is a trial readout, not a PDUFA date or advisory committee (02-connectors.md § Regulatory tier). Company-tier coverage for ZNTL is in ../company.md C.0. The full record is in data/coverage.json.

A. Scientific & clinical assessment

A.1 Mechanism of action and scientific rationale

Some ovarian tumours make far too much of a protein called Cyclin E1. Cyclin E1 pushes cells to divide. When a cell is pushed to divide faster than it can copy its DNA safely, the DNA gets damaged. Scientists call that state replication stress.

A cell under that kind of strain survives by using a brake. The brake is a protein called WEE1. WEE1 pauses cell division so the cell can repair its DNA before splitting.

Azenosertib blocks WEE1. The brake comes off. The tumour cell is forced to divide before it has repaired its DNA, and it tears itself apart — a process called mitotic catastrophe. Healthy cells are not under the same strain, so they are affected far less. This is called synthetic lethality: the tumour’s strain and the drug are each survivable on their own, but lethal together. [VERIFIED — NPJ Precision Oncology 2025, DOI 10.1038/s41698-024-00787-4; Molecular Cancer Therapeutics 2025, DOI 10.1158/1535-7163.MCT-24-1194]

How well is the target validated? The Cyclin E1–WEE1 relationship is well supported in laboratory models across many independent groups, and the specific claim that Cyclin E1 and its partner CDK2 define the vulnerability was published in a peer-reviewed journal before DENALI Part 2 began [VERIFIED — DOI 10.1038/s41698-024-00787-4]. A 2025 peer-reviewed paper co-authored by the company characterises azenosertib’s potency and selectivity across a panel of solid tumours [VERIFIED — DOI 10.1158/1535-7163.MCT-24-1194]. Independent groups have published WEE1-blocking work in breast cancer, Ewing sarcoma, lung cancer and colorectal organoids, and an independent 2023 systematic review of the class found that alterations in TP53 and CCNE1 were the leading candidate predictors of response [VERIFIED — DOIs 10.3390/ijms26125701, 10.1186/s12885-025-13691-2, 10.1016/j.xcrm.2024.101578, 10.1021/acs.jmedchem.4c02541, 10.1016/j.ctrv.2023.102531].

The limit of that check. All of it is laboratory and preclinical work, plus a peer-reviewed description of the molecule. Not one line of DENALI clinical data has been published in a peer-reviewed journal. Everything clinical below comes from conference presentations and company press releases. Independent human-genetics confirmation was again not obtainable, because Open Targets is blocked. [VERIFIED — PubMed, 17 hits, all inspected]

The exact scientific step the next readout must prove. That selecting patients for Cyclin E1 in advance, using the company’s own staining test, produces a response rate clearly above what chemotherapy achieves. Everything else — the mechanism, the selectivity, the dose — is already established well enough. This one step is not. [UNVERIFIED — pending DENALI Part 2]

The honest scientific risk. Blocking WEE1 also removes the brake from healthy bone-marrow cells, which are among the fastest-dividing cells in the body. Low blood counts are therefore not a side effect that better chemistry can design away: they are the mechanism working where it is not wanted. The five-days-on, two-days-off schedule exists to manage exactly that. [VERIFIED — company releases; the interpretation is UNVERIFIED]

A.2 Clinical development plan, timeline, feasibility, resourcing

Trials

Every Zentalis trial above is sponsored by K-Group, Beta, Inc., a wholly owned subsidiary. The 16% chemotherapy figure used as the benchmark throughout this document is the MIRASOL control arm, which is the best available number for what single-agent chemotherapy achieves in this exact population. [VERIFIED — NEJM; FDA]

Feasibility matrix

The timing question the previous version raised is now answered, in the direction it feared. The previous analysis noted that the registry’s measurement window — “up to approximately 12 months from the enrolment of the last subject” — was, taken literally, incompatible with a full 310-patient topline in December 2026, and guessed the year-end topline would have to be Part 2b alone. The company resolved the tension the other way: it kept the integrated readout and moved the date. The 2026-08-06 release confirms Parts 2a and 2b enrolment complete, Part 2c still enrolling, and an integrated topline in H1 2027 “to allow for data maturation post full enrollment”. Two consequences follow. The readout will be larger and more mature than a December 2026 Part 2b-only readout would have been — more patients, longer follow-up, more confirmed responses and durability. And it now includes Part 2c, patients with one to four prior lines including a weekly taxane, a more heavily pre-treated group that plausibly dilutes the headline response rate. [VERIFIED — CT.gov NCT05128825; company release 2026-08-06; the dilution point is UNVERIFIED judgement]

Resourcing sufficiency. The company can still reach the readout, but the cushion the previous version called its most favourable fact has thinned. Cash of $174.6M at 2026-06-30 covers operations into late 2027 by the company’s own statement, against a readout window ending 2027-06-30 — a few months of margin where there used to be nearly a year. Projected cash at the likeliest readout is about $63M. What it cannot fund alone is unchanged: completing a 420-patient Phase 3 and launching a cancer drug cost far more than it holds, so a partnership or a raise follows a good result — and may now precede it. See ../company.md C.3. [VERIFIED — Q2 2026 results; UNVERIFIED — the projections]

A.3 Target label, target product profile, strategic questions, designations

A.3a Target label. Adults with Cyclin E1-positive, platinum-resistant high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer, who have had one to three prior lines of therapy (up to four with prior Elahere or in the taxane-experienced cohort), treated with a single oral agent. [VERIFIED — CT.gov NCT05128825 eligibility criteria]

A.3b Target product profile

A.3c Strategic Go/No-Go questions — Pre-Phase-III (path to registration). Dose-finding is complete and the confirmatory Phase 3 is dosing, so the registration set applies.

A.3d Regulatory designations.

• FDA Fast Track, granted for Cyclin E1-positive platinum-resistant ovarian cancer. It grants more frequent FDA meetings, eligibility for rolling review of a marketing application, and eligibility for priority review. The BPIQ changelog dates the grant to 2026-04-21; a separate source used in an earlier version of this analysis dated it to January 2025. The conflict is flagged, not resolved [VERIFIED — BPIQ note; UNVERIFIED — date]
• FDA Type D meeting held on the accelerated-approval strategy (disclosed 2026-08-06). Not a designation, but the closest thing to one this program gained since the last analysis: the FDA had no objection to the 400 mg dose and “acknowledged the DENALI Part 2 study population, including the 2c cohort, has the potential to support an accelerated approval pathway, subject to the strength of the data and the landscape of approved agents at the time of regulatory action” [VERIFIED — Q2 2026 results release]. The landscape caveat is new, and it is a real condition: an accelerated approval requires an unmet need, and the FDA is reserving the right to judge that need as of 2027–2028, not today
• No Breakthrough Therapy, orphan or priority-review designation was found for this programme in any source read during this sweep. ChEMBL records orphan: 0 [VERIFIED — ChEMBL; absence of evidence in the press feed]

A.4 Target product profile valuation matrix

Calibration examples, not claims about this asset: in oncology each incremental month of overall survival is worth roughly $150–300M of peak-sales potential, and oral formulations command roughly 15–25% price premiums over injectables.

A.5 Evidence quality and endpoints

The central caveat, restated because it is still the whole question. DENALI Part 1b enrolled patients regardless of Cyclin E1 status. The 31.3% figure came from analysing the Cyclin E1-positive patients after the results were in, in a group of 48 people whose 95% confidence interval runs from 18.7% to 46.3% — wide enough to contain both a clear success and a clear failure. Two things weigh in its favour: the Cyclin E1 hypothesis was published in advance and validated in the laboratory, and Part 1b used the same 400 mg dose that Part 2 uses, so the comparison is dose-matched rather than extrapolated. Against it: subgroups found after the fact usually shrink when tested prospectively, there is no rule that says by how much, and the integrated readout now folds in the more heavily pre-treated Part 2c cohort. [VERIFIED facts — SGO 2025, company releases; the shrinkage and dilution risks are UNVERIFIED judgement]

Endpoints

A.5b Key opinion leaders.

The pivotal registry names no overall officials and lists a single site contact, so the investigator panel below is built from the clinical co-authors of the company’s own biomarker publication who hold trial-site affiliations, not from a registry roster. PubMed metadata carries no conflict-of-interest field, so every conflicts-checked entry records where the search was actually made, never a certified absence.

Panel as of. 2026-08-12.

Investigators

Independent voices

Judgement

Dissent

No named voice disagreeing with the endpoint approach was found in this sweep. The table is left empty rather than filled with an invented disagreement.

B. Commercial assessment

B.0 Current treatment algorithm

• First line. Surgery, then platinum-based chemotherapy (carboplatin with paclitaxel), often with bevacizumab. Many patients then take a PARP-inhibitor tablet as maintenance. [VERIFIED — standard of care, reflected in the DENALI eligibility criteria]
• When platinum stops working (the platinum-resistant setting, later lines). Single-agent chemotherapy — pegylated liposomal doxorubicin, paclitaxel, topotecan or gemcitabine — sometimes with bevacizumab. Tumours shrink in only about 16% of patients. [VERIFIED — MIRASOL control arm]
• The one targeted option today. Elahere, an infused antibody-drug conjugate, for the roughly 35–40% of patients whose tumours are FRα-high. It did $690 million of global sales in 2025. [WEB ESTIMATE — AbbVie/GlobalData 2026]

Where azenosertib would fit. As a new oral option in the platinum-resistant setting for the roughly 50% of patients who are Cyclin E1-positive. It targets a different marker from Elahere, so the two mostly serve different patients, with some overlap — and the DENALI and ASPENOVA protocols both require prior Elahere where a patient was eligible for it, which positions azenosertib explicitly after Elahere rather than against it. That makes the drug additive to the current standard rather than a substitute for it, and it means the Cyclin E1-positive population it reaches in practice is largely one that has already exhausted the targeted option. The FDA’s new “landscape of approved agents at the time of regulatory action” caveat makes this positioning double-edged: the unmet need it serves must still exist in 2027–2028. [VERIFIED — CT.gov eligibility criteria, both trials; company release 2026-08-06]

B.1 Competitive landscape and positioning

Where it wins. Azenosertib is the only WEE1 blocker close to approval, and the field behind it remains all Phase 1, chasing narrower genomic niches. It serves a group that is about half of platinum-resistant ovarian cancer and has no targeted option once Elahere is exhausted.

The single fact the thesis rests on is unchanged: whether the Cyclin E1 result holds when patients are selected in advance. Everything else — the head start, the patent life, the FDA alignment, the running confirmatory trial — is downstream of that one number.

Calibration note, not a claim about this asset: oncology first-movers in novel mechanisms have historically shown roughly 3.2× higher peak-sales potential but about 1.8× higher development risk.

B.2 Addressable market

Launch markets: the United States, the top five European markets and Japan. Zentalis has no commercial infrastructure in any of them and has only begun hiring commercial staff.

B.3 Value and feasibility

B.3a Expected peak sales. These figures assume the drug is approved — they are not reduced for the chance the trial fails — and they are before anything owed to Recurium.

The honest way to build this is top-down from a verified comparator, because the bottom-up route needs an epidemiology figure that could not be re-verified. Elahere did $690 million of global sales in 2025, serving the FRα-high 35–40% of platinum-resistant ovarian cancer as the only targeted option [WEB ESTIMATE — AbbVie/GlobalData, 2026]. Cyclin E1-positive is about 50% of the same disease, so the addressable pool is roughly 1.3× larger. Everything below scales that anchor.

The weakest input is the patient count, and it is named rather than smoothed over. The build leans on the Elahere revenue anchor, which is a single verifiable number, and treats the patient count as a derived quantity rather than an input.

Reconciliation with the sell side. Mizuho models roughly $1.5B of unrisked peak sales (2026-07-17, initiation at Outperform, $8 target). Jefferies’ published risk-adjusted ~$417M at a 50% probability of success implies an unrisked ~$834M, the top of the base range. Morgan Stanley’s $511M sits inside it. The build above is therefore consistent with published estimates once their risk adjustment is undone. [WEB ESTIMATE — Mizuho, Jefferies, Morgan Stanley via Investing.com and stocktitan, 2026]

B.3b Feasibility

A correction carried forward from the previous version, still in force. An early version of this analysis asserted that Recurium takes 20% of any sublicensing income. The 20% figure in Zentalis’s filings runs the other way: it is an obligation on Zentera, the Chinese joint venture, to pay Zentalis 20% of sublicensing income it receives. What Zentalis owes Recurium is described only as sublicense fees on consideration received, with no percentage established. [VERIFIED — the Zentera 20% term and the existence of a Recurium sublicensing obligation; UNVERIFIED — the Recurium percentage]

B.4 Product-development risk

Framing questions.

1. Does the development plan support the target product profile claims? Mostly. The pivotal trial pre-selects Cyclin E1-positive patients and measures response rate, which matches both the commercial goal and the approval precedent, and the FDA has now reviewed the strategy without objection. Two gaps: it has no comparison group, and it collects no quality-of-life data, so the “better patient experience than an infusion” claim will have no evidence behind it until ASPENOVA reports.
2. Will the identified risks affect the target product profile? Yes, two of them directly. The blood-count risk threatens the “manageable side effects” claim that justifies a tablet over chemotherapy. The unapproved companion test threatens the “treat only likely responders” claim that justifies the price.
3. If a risk cannot be mitigated, is the asset still differentiated? If severe infections returned at the pivotal dose, being oral and targeted would not compensate and the programme would very likely stop. Safety is the make-or-break risk, and it is the only one on this page that can end the company.

Readout

Sources

The modelled estimate. The registry’s primary completion date (2026-12-01) plus the rule-34 default lag of two to four months to database lock, analysis and topline gives February to April 2027. data/benchmarks/readout-lag.json holds no comparable entry, so the stated default applies and the tag says so. The registry date predates the slip, so this arithmetic leans on a field that may itself move; if primary completion slips toward the registry’s 2027-06-30 study-completion date, the estimate slides right with it.

Window

Basis. The company’s fresh guidance (2026-08-06) names the half-year outright, and the modelled arithmetic — stale registry primary completion plus the default lag — lands inside it, pointing at its earlier-middle part. Likeliest is placed mid-window, slightly past the modelled range, because the stated reason for the delay is data maturation and companies deliver more often in the back half of a freshly guided window than the front. Precision is PERIOD because a half-year is all any source names. Confidence is MEDIUM rather than HIGH because this guidance is six days old and is the row’s first slip — and Part 2c, which the integrated readout waits on, is still enrolling.

Disagreement. UNRESOLVED. The registry’s primary completion date (2026-12-01) points five to seven months earlier than the company’s “1H 2027” and BPIQ’s placeholder. The likeliest explanation is that the registry has simply not yet been edited to reflect the 2026-08-06 guidance — it still lists the study as recruiting — but that is an explanation, not a resolution, and the sources are reported as they stand rather than averaged (rule 24).

Date slippage.

One slip. Eight dated statements, seven transitions, of which six are reiterations and one — the last — is a six-month push. This row was the negative control in the connector documentation for fifteen months, and it is no longer. [VERIFIED — BPIQ note field; company releases]

Attribution

Status. CLEAN — computed by lib/clustering.mjs’s attributionFor over every has_catalyst row on this ticker’s pipeline, 2026-08-12.

Conflicts

Empty — row 17802 is the only has_catalyst: true row among ZNTL’s twelve. Every other azenosertib row reads TBA with no catalyst, and the five discontinued rows carry none.

Note. Blank — status is CLEAN. The one adjacent event worth naming anyway, because it is the same program rather than a different row: the ESMO presentation of DENALI Part 1b overall survival on 2026-10-23 sits inside the run-up period (not the readout window) and can move the stock on this program’s own news months before the topline. That is a within-program event, not an attribution conflict, and the run-up section below treats it as such.

Market and timing for this event

• Plain takeaway. The stock just gave back a fifth of its run on the six-month slip, so the market has already re-priced the delay but not the science. The business is valued at roughly $124M of enterprise value against a base case worth several hundred million a year if approved. The event is now far enough away that the trade and the readout are separable: a run-up into the window, then the binary.
• Months to this catalyst. About 4.7 months to the window’s earliest edge (2027-01-01) and about eight to the likeliest date (2027-04-15), from readout.window above — never from the BPIQ placeholder (rule 23). The date is a half-year, not a day. A nearer, smaller event falls first: overall survival data from DENALI Part 1b at ESMO in Madrid on 23 October 2026, which is a disclosed day.
• Expected move around this event. Not usable as a number, and worse than before. ../company.md C.6 records that the last listed options expiry (2027-01-15) covers only the first two weeks of the readout window, and the near-spot quotes bracket anywhere from 16% to 178%. Report the bracket, never a point estimate. What C.7 does establish is that this stock is capable of 35–50% single-day moves on news.
• Nearest comparable past reaction. The 2026-04-09 dose selection in ../company.md C.7, +46.4% intraday. It is the closest analogue available and it is still not close: a dose decision on an interim look is a smaller event than a pivotal topline. The newest data point runs the other way — a −16% de-rating over three sessions on the timeline slip — and calibrates what pure timing news costs this stock.
• Materiality. Dominant, per ../company.md C.2. It is the only ZNTL row with a disclosed catalyst, sitting against five discontinued programmes and six dormant ones. The stock-direction call below is made consistent with that: a dominant-materiality program means the readout moves the whole equity, not a segment of it (rule 27).
• Date slippage. One slip — see Readout above. The seven-times-repeated year-end guidance broke on 2026-08-06.

Spot. $4.16, read on 2026-08-12, cited from ../company.md C.4. The committed price cache’s last bar is 2026-08-05 ($4.95, pre-slip); the spot is the connector’s live quote.

Scenario prices

Expected value. Applying the 55% probability below to the midpoint of each range — $8.25 on a positive and $1.65 on a miss — gives $5.28, which is +26.9% against the $4.16 spot. This is arithmetic, not advice, and it is not a price target. The figure is higher than the superseded lock’s +17.6% for a mechanical reason worth stating: the shares fell 14% while the scenario midpoints moved much less, so the same probability now buys more asymmetry.

Run-up

Entry and exit

Predicted move and peak

Priority score drivers

Priority score. Priority score 12 · formula_version 1.0.0 — from lib/runup.mjs’s priorityScore over the seven rows above. The PERIOD-precision window caps the score through the date-confidence gate, exactly as designed: a dated topline announcement is the single trigger that would re-score this program sharply upward.

Settlement. Left null at lock time. Settled only on an explicit user request, from a confirmed primary source, against the committed price cache — see 05-prediction-protocol.md § Run-up settlement.

Verdict

What I would do. Watch. The de-rated price is more interesting than the old one, but two things changed against the thesis — the runway cushion and the timeline — and one changed for it, the FDA alignment.

Why. The scientific case is intact and marginally strengthened: the FDA reviewed the accelerated-approval strategy without objecting to the dose, MUIR added a 39% combination response rate, and the integrated readout will be larger and more mature than the year-end version would have been. The market case is more balanced than it looks. Against: the first slip after fifteen months of unchanged guidance, an integrated readout that folds in a harder cohort, a runway that now outlasts the window by months rather than a year, and a landscape caveat from the FDA that Elahere’s entrenchment could deepen by 2027. For: a 16% de-rating on timing news alone, an enterprise value near a quarter of one base-case year of sales, and a disclosed intermediate catalyst (ESMO overall survival, 2026-10-23) inside the run-up period. The honest position is a modest positive lean on the science, held at low confidence on the shares, sized for a total loss.

What would change this. A DENALI Part 2 response rate in the low twenties or below, or any new report of treatment-related deaths or a clinical hold, ends the thesis outright. A weak overall- survival showing at ESMO two-plus months before the topline would be a genuine warning shot. On the other side: a strong ESMO OS median, a pre-readout partnership, or a dated topline announcement — which would also re-score the run-up call sharply upward through the date-confidence gate. A raise before the readout would confirm the financing risk this version elevates.

What to watch.

• 2026-08-14 (days away). 13F filings holding 2026-06-30 positions: whether the five disclosed funds added into the event. No 13F visibility past 2026-03-31 exists today, per the corrected label reading in ../company.md C.5.
• 2026-10-23. ESMO in Madrid: overall survival from DENALI Part 1b, as a rapid oral presentation. Survival data from a single-arm trial cannot prove benefit, but a median clearly above what chemotherapy achieves would strengthen the case, and a weak one would be a warning with the topline still months away.
• Semi-monthly. FINRA short-interest settlements: the short build peaked at 6.15M shares mid-July and covered 9% into 2026-07-31 — before the slip. Whether shorts rebuild into the window is a positioning read the BPIQ field cannot give.
• Q3 2026 results (around November). Cash, the runway wording, any Part 2c enrolment-completion statement — the single operational fact the H1 2027 date now rests on — and whether “1H 2027” is repeated, narrowed, or slips again.
• Any time. The DENALI registry record: its primary completion date still reads 2026-12-01, pre-slip. Its next edit either confirms the new guidance or contradicts it.
• The readout itself. Read the confidence interval, not the point estimate, and read which cohorts the headline number pools. A 30% response rate in the 2a+2b population and a 30% rate diluted across 2c are different filings.

Locked prediction

• Outcome-direction (will the readout succeed on its primary endpoint?): positive — probability 55%, band 42–68% [UNVERIFIED — modelled]. Reasoning: the dose-matched Part 1b result (31.3% in 48 Cyclin E1-positive patients at the same 400 mg dose), a prespecified interim analysis the company acted on by starting a Phase 3 and paying a $7.0M milestone, an FDA Type D review with no objection to the dose and an acknowledged accelerated-approval pathway, a direct precedent (SORAYA) in the identical setting, and a maturer dataset than the superseded call anticipated. Against: the Part 1b subgroup was retrospective with a 95% CI of 18.7–46.3%, prospective replication usually shrinks such estimates, and the integrated readout folds in the heavier-pretreated Part 2c cohort. Three points below the superseded 58%: the 2c dilution risk and the FDA’s landscape caveat on the filing-intent half of the settlement definition slightly outweigh the alignment gained. Jefferies publishes 50% for the programme; this sits above it because the settlement bar below is a readout bar, not an approval bar. The band spans 50 because a single-arm readout is genuinely bimodal; the point is what is scored.
• Stock-direction (which way do the shares move?): up — confidence low — window 2027-01-01 to 2027-07-31, basis: the guided H1 2027 readout window (equal to readout.window earliest to latest), extended one month to absorb a topline that lands in early July. Materiality is dominant per ../company.md C.2, so the readout moves the whole equity, and attribution is CLEAN, so the move is attributable to this event alone. Confidence is low rather than the direction being absent: the outcome view is only 55%, no insider has bought above $2.28 against a $4.16 spot, the runway is tight enough that a financing could land inside the window, and the options market cannot even span the event.
• Scenario prices: positive $6.50–$10.00 · miss $1.00–$2.30
• Expected value: $5.28, +26.9% against spot $4.16 (arithmetic, not advice)
• Run-up: entry $4.16 on 2026-08-12, exit rule T-5 trading days before readout.window.earliest (2027-01-01) — predicted move 0–35%, predicted peak 10–50% around 2026-12 — priority score 12, formula_version 1.0.0
• Settles on the public release of DENALI Part 2 integrated topline results, guided to H1 2027. Positive is defined as: the confirmed objective response rate by RECIST v1.1 in the Cyclin E1-positive primary analysis population, as the company headlines it in the topline release, is 25% or higher, and Zentalis states in the same release that it intends to proceed to an accelerated-approval submission (or that it has FDA agreement to do so). Anything else — a lower response rate, a release that reports the number without a filing intention, or a release that discloses a new clinical hold or new treatment-related deaths — settles as a miss. Primary source: the Zentalis press release and the corresponding SEC Form 8-K.
• Locked: yes · Settled: no — recorded in ../../../data/predictions.json as ZNTL-17802-2026-08-12, superseding ZNTL-17802-2026-08-04.

Program data-quality flags

• Open Targets is blocked (Rate limit exceeded for client: global, four attempts), so the human genetic evidence for CCNE1 and WEE1 in ovarian cancer is not independently confirmed here. Every target-validation claim is tagged to a published paper instead.
• The registry’s primary completion date (2026-12-01) predates the 2026-08-06 slip and now points five to seven months earlier than the company’s own guidance. Recorded as an UNRESOLVED disagreement in the Readout section rather than resolved by assumption.
• ChEMBL records oral: false for CHEMBL5095036, contradicting every trial record, and max_phase: 2, lagging the Phase 3 ASPENOVA study. Both are connector errors and neither is used.
• The Recurium royalty rate is reported inconsistently across filing descriptions — “mid- to high-single digit percentage” in the description read this sweep, “low to mid-single digit” in an earlier one. Flagged, not resolved, and not averaged.
• The Recurium sublicensing percentage is not established. The 20% figure carried by an early version of this analysis is a Zentera-to-Zentalis obligation in the filings. See B.3b.
• The FDA Fast Track grant date conflicts between sources (2026-04-21 per the BPIQ changelog against January 2025 previously). Flagged, not resolved.
• No DENALI clinical data has been published in a peer-reviewed journal. Every clinical figure in this document comes from a conference presentation or a company press release, read through secondary coverage rather than from the primary abstract.
• PubMed returned 17 hits against the 15-article threshold. All 17 were retrieved; one is an unrelated 2014 physical-chemistry paper matching on the string “ZN-c3”.
• PubMed metadata carries no conflict-of-interest field, so the A.5b conflicts-checked entries record where each search was performed, never a certified absence of conflicts.
• Peak-sales inputs are third-party estimates and assume approval. They exclude everything owed to Recurium.
• The committed price cache ends 2026-08-05, the session before the slip, so the entry price and the −16% reaction read from the connector’s live quote rather than committed daily bars.
• Company-level flags for ZNTL are in ../company.md C.8.